All In Biotech

Drug Trial Radar · NCT02247349

BMS-986012 in Relapsed/Refractory SCLC

A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

106

Actual

Start

Nov 14, 2014

Primary completion

Dec 21, 2022

Study completion Dec 22, 2022

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Sep 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.

Conditions

  • Small Cell Lung Cancer

Interventions

  • BMS-986012 (anti-fucosyl-GM1)Biological

  • NivolumabBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: From first dose to 100 days post last dose (Up to 64 months)
  2. Number of Participants With Serious Adverse Events (SAEs)Time frame: From first dose to 100 days post last dose (Up to 64 months)
  3. Number of Participants With Adverse Events (AEs) Leading to DiscontinuationTime frame: From first dose to 100 days post last dose (Up to 64 months)
  4. Number of Participants Who DiedTime frame: From first dose to 100 days post last dose (Up to 64 months)
  5. Number of Participants With Abnormal Hepatic TestTime frame: From first dose to 100 days post last dose (Up to 64 months)

Locations

16 sites in 7 countries. Site status is shown where the registry gives one.

  • Local Institution - 0004

    New York, New York

  • Local Institution - 0001

    Durham, North Carolina

  • Local Institution - 0021

    Winston-Salem, North Carolina

  • Local Institution - 0020

    St Leonards, New South Wales, Australia

  • Local Institution - 0011

    Brisbane, Queensland, Australia

  • Local Institution - 0002

    Clayton, Victoria, Australia

  • Local Institution - 0015

    Ghent, Belgium

  • Local Institution - 0012

    Liège, Belgium

  • Local Institution - 0003

    Edmonton, Alberta, Canada

  • Local Institution - 0017

    Halifax, Nova Scotia, Canada

  • Local Institution - 0019

    Hamilton, Ontario, Canada

  • Local Institution - 0010

    London, Ontario, Canada

  • Local Institution - 0007

    Toronto, Ontario, Canada

  • Local Institution - 0013

    Nijmegen, Netherlands

  • Local Institution - 0009

    San Juan, Puerto Rico

  • Local Institution - 0008

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.